Manufacturing

Olivia Hughes, olivia.hughes@spherefluidics.com, is a senior marketing associate at Sphere Fluidics.

Articles

Growing demand for bispecific antibodies increases the need for automated and miniaturized high throughput screening capabilities.

Using Picodroplet Technology to Optimize Bispecific Cell Lines

Samsung Biologics and Kineta have entered into a strategic partnership for drug product manufacturing services and to support an IND filing of a novel antibody therapeutic. 

Samsung Biologics Partners with Kineta for Anti-VISTA Antibody Immunotherapy

Sparx Therapeutics will build its first commercial manufacturing facility in Yangzhou, China, for antibody drug production.

Sparx Therapeutics to Build Commercial Antibody Manufacturing Facility in China

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Understanding the process and product goals is just the first step to a holistic approach to process development.

Defining a Holistic Approach to mAb Purification Processes

The extended manufacturing agreement between Pinteon and Lonza enables future clinical production of PNT001, a novel Tau antibody therapeutic that targets Alzheimer's disease and traumatic brain injury.

Pinteon and Lonza Extend Collaboration for Manufacturing Antibody Therapeutic

FDA has granted accelerated approval to Biogen for Aduhelm (aducanumab), a new mAb treatment for Alzheimer’ disease.

FDA Grants Accelerated Approval for Biogen’s Alzheimer’s Drug

Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe.

Avantor to Increase Global Capacity for Single-Use Technologies

Samsung and TG Therapeutics have expanded their 2018 contract manufacturing deal for the supply of TG’s ublituximab, an investigational anti-CD20 monoclonal antibody. 

Samsung and TG Therapeutics to Expand mAb Manufacturing Collaboration 

Through the agreement, Lonza will use its fully integrated end-to-end program, Ibex Design, to manufacture cGMP material for the mAb while supporting the process from gene to IND.

Lonza Partners with aTyr Pharma for mAb Manufacturing

Eli Lilly has modified its purchase agreements with the US government for its emergency use authorized COVID-19 neutralizing antibody therapies, bamlanivimab and etesevimab, to be supplied and used together rather than individually.

Manufacturing, Monoclonal Antibodies